Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The session is scheduled for September 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of the company's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) – synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland.
The invitation to present at a major healthcare conference underscores growing investor interest in psychedelic-inspired treatments for mental health. Mental health disorders affect millions worldwide, and existing therapies often fail to provide durable relief for many patients. Helus Pharma's focus on NSAs could offer a new mechanism of action if clinical trials succeed. The FDA's Breakthrough Therapy Designation for HLP003 signals regulatory recognition of the drug's potential, which may expedite development and review. For investors, the conference provides an opportunity to assess the company's progress and strategy directly from its CEO. For the broader industry, it highlights the increasing acceptance of psychedelic-based medicines within mainstream pharmaceutical development. The outcome of late-stage trials for HLP003 and Phase 2 results for HLP004 will be critical in determining whether Helus Pharma can deliver on its promise to transform mental health treatment. The webcast can be accessed via the company's investor relations page, and updates are available in the company's newsroom at https://ibn.fm/HELP.
